Press coverage about Eli Lilly and (NASDAQ:LLY
) has been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eli Lilly and earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.5588537037632 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Eli Lilly and (LLY
) traded up 0.34% during mid-day trading on Wednesday, reaching $86.74. 927,497 shares of the company’s stock were exchanged. The firm’s 50-day moving average is $81.60 and its 200 day moving average is $82.05. The stock has a market capitalization of $91.51 billion and a PE ratio of 37.53. Eli Lilly and has a 1-year low of $64.18 and a 1-year high of $87.16.

ILLEGAL ACTIVITY NOTICE: “Eli Lilly and (LLY ) Receiving Somewhat Positive News Coverage, Analysis Shows” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Insider Buying and Selling by Quarter for Eli Lilly and (NASDAQ:LLY

Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with Analyst Ratings Network's FREE daily email newsletter.